Real-World Effectiveness of Gliclazide MR vs. Sitagliptin as Second-Line Therapy in People with Type 2 Diabetes Uncontrolled on Metformin

被引：0
|
作者：
Zaccardi, Francesco
Cortese, Viviana
Jacquot, Emmanuelle
Tyrer, Freya
Seidu, Samuel
Davies, Melanie J.
Khunti, Kamlesh
机构：
来源：
DIABETES | 2020年 / 69卷
关键词：
D O I：
10.2337/db20-1062-P
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1062-P
引用
收藏
页数：3
相关论文
共 50 条
  • [41] The Role of Real-World Evidence in Treatment Decision-Making, Regulatory Assessment, and Understanding the Perspectives of People with Type 2 Diabetes: Examples with Gliclazide MR
    Kamlesh Khunti
    Mussa Almalki
    Juliana C. N. Chan
    Aslam Amod
    Diabetes Therapy, 2023, 14 : 1609 - 1625
  • [42] Tolerability and effectiveness of gliclazide MR-SGLT2i combination in type 2 diabetes people fasting during Ramadan: a subgroup analysis of the real-world DIA-RAMADAN study
    Hassanein, M.
    Durocher, A.
    Cortese, V.
    DIABETOLOGIA, 2023, 66 (SUPPL 1) : S73 - S73
  • [43] Comparing the effectiveness and cost-effectiveness of sulfonylureas and newer diabetes drugs as second-line therapy for patients with type 2 diabetes
    Franchi, Matteo
    Pellegrini, Giacomo
    Avogaro, Angelo
    Buzzetti, Giuliano
    Candido, Riccardo
    Cavaliere, Arturo
    Consoli, Agostino
    Marzona, Irene
    Mennini, Francesco Saverio
    Palcic, Stefano
    Corrao, Giovanni
    BMJ OPEN DIABETES RESEARCH & CARE, 2024, 12 (03)
  • [44] The Association Between Second-Line Oral Antihyperglycemic Medication on Types of Dementia in Type 2 Diabetes: A Nationwide Real-World Longitudinal Study
    Kim, Won Jun
    Noh, Jung Hyun
    Han, Kyungdo
    Park, Cheol-Young
    JOURNAL OF ALZHEIMERS DISEASE, 2021, 81 (03) : 1263 - 1272
  • [45] Long-term sustainability of glycaemic achievements with second-line antidiabetic therapies in patients with type 2 diabetes: A real-world study
    Montvida, Olga
    Shaw, Jonathan E.
    Blonde, Lawrence
    Paul, Sanjoy K.
    DIABETES OBESITY & METABOLISM, 2018, 20 (07): : 1722 - 1731
  • [46] Type 2 diabetes: second-line antidiabetic therapy in early pregnancy
    Clauss, Maria
    ZEITSCHRIFT FUR GEBURTSHILFE UND NEONATOLOGIE, 2024, 228 (02): : 119 - 119
  • [47] COST-EFFECTIVENESS OF SAXAGLIPTIN VERSUS ACARBOSE AS SECOND-LINE THERAPY IN TYPE 2 DIABETES IN CHINA
    Gu, S.
    Shao, H.
    Zeng, Y.
    Shi, L.
    Dong, H.
    VALUE IN HEALTH, 2016, 19 (07) : A898 - A898
  • [48] Cost-Effectiveness of Saxagliptin versus Acarbose as Second-Line Therapy in Type 2 Diabetes in China
    Gu, Shuyan
    Zeng, Yuhang
    Yu, Demin
    Hu, Xiaoqian
    Dong, Hengjin
    PLOS ONE, 2016, 11 (11):
  • [49] Real-World Clinical Effectiveness and Cost Savings of Liraglutide Versus Sitagliptin in Treating Type 2 Diabetes for 1 and 2 Years
    Qian Li
    Rahul Ganguly
    Michael L. Ganz
    Cory Gamble
    Tam Dang-Tan
    Diabetes Therapy, 2018, 9 : 1279 - 1293
  • [50] Oral Semaglutide vs. Empagliflozin Added On to Metformin Monotherapy in Uncontrolled Type 2 Diabetes: PIONEER 2
    Montanya, Eduard
    Rosenstock, Julio
    Canani, Luis H.
    Deerochanawong, Chaicharn
    Gumprecht, Janusz
    Lindberg, Soren
    Lingvay, Ildiko
    Sondergaard, Anette L.
    Treppendahl, Marianne
    Rodbard, Helena W.
    DIABETES, 2019, 68
12345